267 related articles for article (PubMed ID: 23765033)
1. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease.
Steenholdt C; Ainsworth MA; Tovey M; Klausen TW; Thomsen OO; Brynskov J; Bendtzen K
Ther Drug Monit; 2013 Aug; 35(4):530-8. PubMed ID: 23765033
[TBL] [Abstract][Full Text] [Related]
2. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohn's disease: post hoc analysis of a randomized controlled trial.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
Am J Gastroenterol; 2014 Jul; 109(7):1055-64. PubMed ID: 24796769
[TBL] [Abstract][Full Text] [Related]
3. Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn's disease.
Steenholdt C
Dan Med J; 2013 Apr; 60(4):B4616. PubMed ID: 23651723
[TBL] [Abstract][Full Text] [Related]
4. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
[TBL] [Abstract][Full Text] [Related]
5. Monitoring functional serum antitumor necrosis factor antibody level in Crohn's disease patients who maintained and those who lost response to anti-TNF.
Yamada A; Sono K; Hosoe N; Takada N; Suzuki Y
Inflamm Bowel Dis; 2010 Nov; 16(11):1898-904. PubMed ID: 20310016
[TBL] [Abstract][Full Text] [Related]
6. Magnitude of Increased Infliximab Clearance Imposed by Anti-infliximab Antibodies in Crohn's Disease Is Determined by Their Concentration.
Edlund H; Steenholdt C; Ainsworth MA; Goebgen E; Brynskov J; Thomsen OØ; Huisinga W; Kloft C
AAPS J; 2017 Jan; 19(1):223-233. PubMed ID: 27739011
[TBL] [Abstract][Full Text] [Related]
7. Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum.
Wang SL; Ohrmund L; Hauenstein S; Salbato J; Reddy R; Monk P; Lockton S; Ling N; Singh S
J Immunol Methods; 2012 Aug; 382(1-2):177-88. PubMed ID: 22691619
[TBL] [Abstract][Full Text] [Related]
8. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab.
Ternant D; Mulleman D; Degenne D; Willot S; Guillaumin JM; Watier H; Goupille P; Paintaud G
Ther Drug Monit; 2006 Apr; 28(2):169-74. PubMed ID: 16628126
[TBL] [Abstract][Full Text] [Related]
9. A rapid assay for on-site monitoring of infliximab trough levels: a feasibility study.
Corstjens PL; Fidder HH; Wiesmeijer KC; de Dood CJ; Rispens T; Wolbink GJ; Hommes DW; Tanke HJ
Anal Bioanal Chem; 2013 Sep; 405(23):7367-75. PubMed ID: 23836086
[TBL] [Abstract][Full Text] [Related]
10. Generation of a Highly Specific Monoclonal Anti-Infliximab Antibody for Harmonization of TNF-Coated Infliximab Assays.
Van Stappen T; Brouwers E; Tops S; Geukens N; Vermeire S; Declerck PJ; Gils A
Ther Drug Monit; 2015 Aug; 37(4):479-85. PubMed ID: 25525757
[TBL] [Abstract][Full Text] [Related]
11. Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.
Steenholdt C; Palarasah Y; Bendtzen K; Teisner A; Brynskov J; Teisner B; Nielsen CH
Aliment Pharmacol Ther; 2013 Jun; 37(12):1172-83. PubMed ID: 23650912
[TBL] [Abstract][Full Text] [Related]
12. Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab.
Hernández-Breijo B; Chaparro M; Cano-Martínez D; Guerra I; Iborra M; Cabriada JL; Bujanda L; Taxonera C; García-Sánchez V; Marín-Jiménez I; Barreiro-de Acosta M; Vera I; Martín-Arranz MD; Mesonero F; Sempere L; Gomollón F; Hinojosa J; Gisbert JP; Guijarro LG;
Biochem Pharmacol; 2016 Dec; 122():33-41. PubMed ID: 27664854
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
[TBL] [Abstract][Full Text] [Related]
14. SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT.
Teixeira FV; Sassaki LY; Saad-Hossne R; Baima JP; Magro DO; Coy CSR; Kotze PG
Arq Gastroenterol; 2018; 55(2):192-197. PubMed ID: 30043873
[TBL] [Abstract][Full Text] [Related]
15. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.
Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Ainsworth MA
Scand J Gastroenterol; 2011 Mar; 46(3):310-8. PubMed ID: 21087119
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.
Ainsworth MA; Bendtzen K; Brynskov J
Am J Gastroenterol; 2008 Apr; 103(4):944-8. PubMed ID: 18028512
[TBL] [Abstract][Full Text] [Related]
17. Significance of low level infliximab in the absence of anti-infliximab antibodies.
Ungar B; Anafy A; Yanai H; Ron Y; Yavzori M; Picard O; Fudim E; Loebstein R; Kopylov U; Chowers Y; Dotan I; Eliakim R; Ben-Horin S
World J Gastroenterol; 2015 Feb; 21(6):1907-14. PubMed ID: 25684959
[TBL] [Abstract][Full Text] [Related]
18. Routinely utilized in-house assays for infliximab, adalimumab and their anti-drug antibody levels.
Ogrič M; Žigon P; Drobne D; Štabuc B; Sodin-Semrl S; Čučnik S; Praprotnik S
Immunol Res; 2018 Dec; 66(6):726-736. PubMed ID: 30569379
[TBL] [Abstract][Full Text] [Related]
19. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.
Baert F; Noman M; Vermeire S; Van Assche G; D' Haens G; Carbonez A; Rutgeerts P
N Engl J Med; 2003 Feb; 348(7):601-8. PubMed ID: 12584368
[TBL] [Abstract][Full Text] [Related]
20. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies.
Svenson M; Geborek P; Saxne T; Bendtzen K
Rheumatology (Oxford); 2007 Dec; 46(12):1828-34. PubMed ID: 18032541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
